Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
A Double-Blind, Placebo-Controlled Study of Circadin™ for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30382
- Sleep Disorders Center of Atlanta
-
-
New York
-
New York, New York, United States, 10019
- Clinlabs, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects aged 20-80, having no conscious perception of light.
- Meeting the criteria for diagnosing Non-24h cycle in the clinical setting: 1) difficulty initiating sleep or difficulty in awakening, 2) progressive delay of sleep phase with inability to maintain entrainment to 24-hour-day, and 3) presence of the sleep pattern for at least six weeks.
- Average total night sleep duration of less than 6 hours per night for at least six weeks.
- Ability to ingest oral medication and participate in all scheduled evaluations.
- Signing of the Informed Consent approved by the Ethics Committee. The Informed Consent will be written in both Braille and black-and-white forms for blind subject and sighted witness.
- Education or a work history sufficient to exclude mental retardation.
- Stable medications for non-excluded concurrent medical conditions for four weeks prior to the screening visit.
Exclusion Criteria:
- Presence of medical disorders other than those related to blindness and medical treatment that may influence melatonin production, sleep or alertness. To be ascertained by medical history, complete physical examination including ECG and general biochemical work-up including complete blood count, serum chemistries, and urine analysis.
- Presence of a psychiatric or mental disorder to be assessed by a structured psychiatric interview performed by a trained individual.
- History of seizure disorders.
- Irregular lifestyle or life pattern (e.g. shift workers and patients unable to keep the study routine).
- Presence of a sleep problem revealed that may explain the subjects' complaints, such as sleep disordered breathing, restless leg syndrome or periodic limb movement syndrome.
- Use of benzodiazepines or other hypnotics during the study and preceding two weeks or 5 half lives whichever is longer.
- Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists
- Use of melatonin during preceding two weeks
- Use of psychiatric medications during the study and preceding three months.
- History of autoimmune diseases
- Pharmacological immuno-suppression.
- Pregnancy or lactation, child-bearing potential with a lack of adequate contraception.
- History of severe pathology likely to recur during or immediately after the study.
- Participation in a clinical trial with any investigational agent within two months prior to study enrollment.
- Patients incapable of performing the daily call to the study IVRS system and reporting on the questionnaires.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
one tablet per day 2 hours before going to bed
|
|
Experimental: Circadin
Circadin is 2 mg of prolonged release melatonin
|
2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total sleep time
Time Frame: six weeks
|
six weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Daily diary records of sleep latency, sleep maintenance , total duration of naps;
Time Frame: six weeks
|
six weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alan Lankford, PhD, Sleep Disorders Center of Atlanta
- Principal Investigator: Gary Zammit, PhD, Clinlabs, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Dyssomnias
- Eye Diseases
- Neurologic Manifestations
- Occupational Diseases
- Sensation Disorders
- Vision Disorders
- Chronobiology Disorders
- Sleep Wake Disorders
- Blindness
- Sleep Disorders, Circadian Rhythm
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Protective Agents
- Antioxidants
- Melatonin
Other Study ID Numbers
Other Study ID Numbers
- CIRCADIN 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.